HOME >> MEDICINE >> NEWS
Treatment-Resistant Depression: Results of Latest Electromagnetic Stimulation Study Show Promise

eters below the brain's surface. Unlike ECT for depression, rTMS does not require anesthesia or analgesics."

Study subjects were antidepressant-free for one week prior to rTMS and received 10 daily treatments (10 trains of five seconds each, 25 seconds apart) at a frequency of 10 Hz. Seventy-eight percent of patients experienced mild-moderate discomfort at the site of stimulation, two patients who experienced severe pain in the treatment site dropped out of the study and eight percent of patients experienced a posttreatment headache.

The mean age of patients treated was 52 years. " rTMS seems most promising for older adults and for treatment-resistant patients with depression," says Dr. McDonald, who directs the Fuqua Center for Late-Life Depression at Wesley Woods.

Also collarborating on the study were Charles M. Epstein, M.D., associate professor of neurology at Emory; Liquong He, M.D., formerly with Emory; Autumn L. Clark, B.S., study coordinator in Emory's department of psychiatry and behavioral sciences; Fred A. Marstellar, Ph.D., associate professor of psychiatry and behavioral sciences at Emory; and John Woodard, Ph.D., of the Georgia State University Memory Assessment Clinic.

The study was supported by a private grant from the Fuqua Foundation.


'"/>

Contact: Sarah Goodwin
sgoodwi@emory@emory.edu
404-727-3366
Emory University Health Sciences Center
17-May-1999


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
9. Results of NUVANCE phase I/II asthma trial presented
10. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
11. UI Study Yields Encouraging Results For New Breast Cancer Treatment

Post Your Comments:
(Date:10/31/2014)... In an effort to expand services and improve efficiency ... will soon offer orthodontics at his Oral & Maxillofacial Surgery ... , To build upon the high degree of care and ... known for, Dr. Jamali is welcoming an orthodontist that is ... as UCLA, Stanford and UCSF. He added that the new ...
(Date:10/31/2014)... 2014 Phoenix dentist , Dr. Christy, ... November. Whether patients simply need routine care or have a ... than now to get that necessary care. The right dental ... routine and even essential treatments due to financial concerns. Throughout ... on any treatments offered by the team at Christy Dental ...
(Date:10/31/2014)... Uniwigs.com newly arrived flip in hair extensions are ... itself around people’s heads with a transparent miracle wire undetectable ... comes with adjustable loops, which are improved over the basic ... now adjust the wire to best fit the size of ... generation of flip ins, they simply need to adjust the ...
(Date:10/31/2014)... 31, 2014 Med-Care Diabetic & Medical ... highest principles of patient care and service, announced a ... and wellness website, to provide an online Diabetes ... , The Diabetes Health Center will provide topical information ... living with diabetes. Content will feature advice from leading ...
(Date:10/31/2014)... FRIDAY, Oct. 31, 2014 (HealthDay News) -- A few simple ... cope with, a sleep expert says. "Adjusting to the ... bit easier than handling the time change in the spring. ... sleep for the fall time change," Dr. Praveen Rudraraju, director ... in Mount Kisco, N.Y., said in a hospital news release. ...
Breaking Medicine News(10 mins):Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2Health News:UniWigs Unveiles New Generation of Flip In Hair Extensions 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 3Health News:Make the Most of This Weekend's Time Change 2
(Date:10/31/2014)... 31, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug ... a conference call to discuss the clinical results ... the company,s proprietary oral insulin capsules, to treat ... at 10:00 a.m. Eastern time. Shareholders ...
(Date:10/31/2014)... 31, 2014 Investor-Edge has initiated ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow ...
(Date:10/31/2014)... 3, 2014 British Journal ... BPH to discuss "male orgasmic dysfunction" with their doctor ... treat prostate symptoms while preserving sexual function   ... publication of a paper in the British Journal of ... prostate to discuss with their doctors the likely impact ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2
Cached News: